Epichem is a globally competitive business with a strong track record of exporting to customers throughout the world. This has resulted in a number of export awards from both the Western Australian and Australian Governments.
|Epichem is a major part of DNDi's Chagas Lead Optimisation Consortium, proving synthetic and medicinal chemistry expertise to the project. The consortium has made great strides and has a number of novel compounds in preclinical development. The success of the consortium has been recognized by DNDi which presented it with the Partnership of the Year for 2011.|
|Epichem's Head of Drug Discovery, Dr Martine Keenan, won the MedChemComm poster prize at the 16th SCI/RSC Medicinal Chemistry Symposium in Cambridge, UK. The poster presents the identification and development of novel compounds for the treatment of Chagas disease. This award winning work is the result of a consortium established by not-for-profit, Drugs for Neglected Diseases initiative (DNDi). Click Here to view the winning poster.|
|Epichem has a collaborative research project with Curtin University to develop a small molecule orally available replacement for insulin for the treatment of diabetes. The project won the Start Up category in Western Australia's Innovator of Year Award for 2011. Click Here for more detailed information on this project.|